On Wednesday, Pharmaceutical Giant Pfizer Agreed to Buy Baxter International's Vaccines Unit Worth $635 Million

Pfizer Forms Global Strategic Alliance with Merck KGaA, Germany, to Jointly Develop and Commercialize Anti-PD-L1 to Accelerate Presence in Immuno-Oncology

PD-L1 Antibody Clinical Results Consistent with Class; Interim Data Demonstrated A Complete and Partial Responses in Ovarian Cancer and NSCLC Up to 20 High Priority Immuno-Oncology Clinical Development Programs, Including Up to 6 Registration Trials, Expected to Commence in 2015 November 17, 2014 Pfizer Inc. announced today that it has entered into an agreement with Merck KGaA, Darmstadt, Germany, to …

Michael Hanna Vaccinogen cancer vaccine prostate cancer

The Problem with Cancer Vaccines

  You can’t treat a heterogeneous disease with a homogeneous treatment. That was the takeaway message from Vaccinogen’s founder at the World Vaccines Congress Europe Vaccine Nation caught up with Michael Hanna, the founder of Vaccinogen and creator of autologous patient-specific tumour cell vaccine OncoVAX, to discuss why there have been so many high-profile cancer vaccine failures and how this has affected …

Merck Tecemotide Cancer Vaccine Fails Phase II Clinical Trial Goal

Merck’s therapeutic cancer vaccine candidate, tecemotide, has shown no treatment effect in any trial endpoints Merck’s experimental therapeutic cancer vaccine,  in partnership with Oncothyreon,  has recently shown disappointing clinical trial results after the drug failed to meet its primary endpoint, as well as several other secondary endpoints. Many pharmaceutical companies are currently developing therapeutic cancer vaccines, and these are the …

Batu Biologics Achieves Goal in Successful Crowdfunding Campaign

Biotech Startup Aims for FDA Approval for Novel Anti-Angiogenic Cancer Vaccine August 18th, 2014 Using a fundraising approach seldom seen in the life sciences sector, Batu Biologics, an immunotherapy company working to develop the first anti-angiogenic cancer vaccine, has successfully raised $100,000 through the Indiegogo crowdfunding platform. Batu Biologics launched the crowdfunding campaign in June 2014 to fund the completion …

Regen BioPharma Has Reported Progress in Development of dCellVax: A Therapeutic Cancer Vaccine

Regen BioPharma Advances Towards Breast Cancer Immunotherapy

Regen BioPharma Has Reported Progress in Development of dCellVax: A Therapeutic Cancer Vaccine On the 1st of August 2014, Regen BioPharma reported on progress on its therapeutic cancer vaccine dCellVax, which stimulates the immune system of patients to selectively kill tumors. Thomas Ichim, the Chief Scientific Office of Regen BioPharma, said in a statement that ‘we are please to announce …

vaccine manufacturers

Top 3 Sparks of Interest for Leading Vaccine Academics

Recently we undertook the research for the 15th annual World Vaccine Congress. As part of that research, we spoke to leading vaccine academics from the likes of University of Oxford and Erasmus MC to find out what they thought were the most interesting trends in industry at the moment. These were the top 3: 1. The renaissance of veterinary vaccines …

Vaccine Asia Live: Current Situation of Cervical Cancer Vaccines

Levent Shih-Jen Liu, the Associate Investigator of National Health Research Institute in Taiwan, moderated the Round Table Discussion, covering the topic of cervical cancer vaccines. Human Papilloma Virus (HPV) Vaccine, a vaccine developed to prevent cervical cancer among women, has been introduced in many countries around the world, including those in Asia. Through valuable inputs from each delegate, a clear …

Vaccine

Vaccine Asia Live: Novel Vaccines for Emerging Diseases

Most vaccines developed target infectious diseases and cancer, with cancer vaccines being listed more under therapeutic vaccines. To enlighten us on vaccines for infectious diseases, Ms Zhang Xiaoshu, Director of Business Development at BravoBio, China, presented on the topic of Novel Vaccines for Emerging Diseases. BravoBio was founded in 2011 with its  headquarters in Shanghai and multiple sites in China. …